Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-PPX fitusiran switching study in hemophilia with inhibitors
NL-OMON46351Phase 3Withdrawn
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Annualized Bleeding Rate. Planned start May 2018; status: withdrawn.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON46351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46351.